Moore Capital Management’s Oaktree Acquisition Corp III Life Sciences Warrant OACCW Stock Holding History

Moore Capital Management’s Portfolio OACCW Stock Details OACCW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.8K	Hold	105,000	–	–	﹤0.01%	596
2026 Q1	$78.8K	Hold	105,000	–	–	﹤0.01%	504
2025 Q4	$74.5K	Hold	105,000	–	–	﹤0.01%	569
2025 Q3	$78.8K	Hold	105,000	–	–	﹤0.01%	537
2025 Q2	$89.3K	Buy	+105,000	New	+$81K	﹤0.01%	464

Other funds holding OACCW

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

DAM

Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BGGS

Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Moore Capital Management's OACCW Position: Q2 2026 in Review

Moore Capital Management held its Oaktree Acquisition Corp III Life Sciences Warrant (OACCW) position steady in Q2 2026 at 105,000 shares worth $98.8K. The position accounts for ﹤0.01% of the portfolio, ranked #596.

Moore Capital Management first reported a position in OACCW in Q2 2025 and has held it in 5 quarters since. 27 funds tracked by Wall St. Rank hold OACCW as of Q2 2026.

Moore Capital Management held 105,000 shares of Oaktree Acquisition Corp III Life Sciences Warrant worth $98.8K as of Q2 2026.
Moore Capital Management left its Oaktree Acquisition Corp III Life Sciences Warrant share count unchanged in Q2 2026.
Oaktree Acquisition Corp III Life Sciences Warrant made up ﹤0.01% of Moore Capital Management's portfolio in Q2 2026, its #596 holding.
Moore Capital Management first reported a position in Oaktree Acquisition Corp III Life Sciences Warrant in Q2 2025 and has held it in 5 quarters since.
27 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences Warrant as of Q2 2026.

Based on Moore Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.